Investigators from the University of Michigan and affiliated organizations published data from a study that aimed to investigate the role of cyclin-dependent kinase 12 (CDK12) in prostate cancer (PCa). Both in vivo and in vitro systems were developed to test the impact of Cdk12 ablation in the context PCa.
Starting with a study of how mutations affect sensitivity to 10 molecularly targeted drugs, researchers have laid the foundations for a prospective, systematic approach to understanding the genetic mechanisms behind cancer drug resistance. These insights will inform the development of drugs that avoid resistance emerging. For existing drugs, it will be possible to better tailor treatment and to identify second-line therapies for patients whose tumors become resistant.
During an Innovation Ignited webinar sponsored by Johnson & Johnson, experts talked about how precision medicine has helped advance the field of oncology and how those lessons can be applied to immunology. Advancements in precision medicine have helped oncologists know which drugs are most likely to help patients as their tumors advance and mutate.
Xuanzhu Pharma Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified compounds acting as diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.
Prostate cancer accounts for 3.8% of total cancer-related deaths worldwide. The combination of docetaxel and androgen deprivation therapy is useful in the management of the disease, but unfortunately, prostate cancer cells become resistant to docetaxel over time.
Shenzhen Chipscreen Biosciences Co. Ltd. has submitted an IND application for CS-231295 tablets for the treatment of tumors, and the application has been accepted by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA).
Poseida Therapeutics Inc. has announced the nomination of a new development candidate under its collaboration with F. Hoffmann-La Roche Ltd., triggering a milestone payment from Roche to Poseida.
RSS
